We announced the closing of our $140 million Series B financing. – Harbinger Health
Harbinger Health shared on LinkedIn:
“Today, we announced the closing of our $140 million Series B financing.
We’re grateful for the support of our investors, including Flagship Pioneering, Pictet Group, Partners Group Investment and Catalyst, M&G Investments’ purpose-led private assets strategy, among other global institutional investors.
With this funding, we will accelerate the advancement of our proprietary two-tier testing model for early-stage cancers, expand our team, and support the completion of our ongoing CORE-HH study, as well as initiate additional clinical studies in high-risk populations.
We’re thrilled to be taking another step toward our goal of making early-stage cancer screening accessible on a global scale.”
For details click here.
For the video click here.
Source: Harbinger Health/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023